They need a partner to commercialize Lympro. Because they don't have sufficient cash to take care of an own sales force and production facility and so on.
They need to start primate trials for MANF in Parkinon disease to know the exact dose range to start a first-in human trial (phase 1) BUT also need to see the results whether the collaboration with the ledical device company works to put an implant in the brain which can release MANF.
They need to start orphan drug deignation for other indications for MANF which could be succesfull sooner than in PD.
All cost money, so I see a big capital raise when they list up. IMO the stock is therefore overbought now and should go back to $.02 at least before it is buy-worthy for me.